Bullish Options Positioning in IBM (IBM) Target Upside in Shares Ahead of Earnings Announcement Tonight -Susquehanna

IBM (IBM) PT Raised to $125 at Societe Generale, Reiterates Sell

January 22, 2020 7:57 AM EST

Societe Generale analyst Richard Nguyen raised the price target on IBM (NYSE: IBM) to $125.00 while maintaining a Sell rating.

Says 'a quarter does not make a trend."... More

IBM (IBM) PT Raised to $164 at Morgan Stanley

January 22, 2020 6:40 AM EST

Morgan Stanley analyst Katy Huberty raised the price target on IBM (NYSE: IBM) to $164.00 (from $155.00) while maintaining a Equalweight rating.

The analyst comments "4Q showcased Red Hat synergies and budget flush but higher levels of investment in 2020 pressure PTI and FCF guidance relative to consensus... More

IBM (IBM) PT Raised to $138 at Cantor Fitzgerald

January 22, 2020 6:37 AM EST

Cantor Fitzgerald analyst Drew Kootman raised the price target on IBM (NYSE: IBM) to $138.00 (from $133.00) while maintaining a Neutral rating.

The analyst comments "We view a return to consistent organic growth and margin expansion as necessary for sustainable multiple expansion from current levels.... More

IBM (IBM) spreaders purchasing weekly calls into EPS and outlook

January 21, 2020 2:16 PM EST

IBM (NYSE: IBM) January weekly call option implied volatility is at 63, February is at 24; compared to its 52-week range of 14 to 33 into the expected release of quarter results today after the bell. Call put ratio 1.9 calls to 1 put with focus on January weekly calls.

... More

Pre-Open Stock Movers 01/17: (TLRD) (PLAY) (PRGS) Higher (DRRX) (EXPD) (JBHT) Lower (more...)

January 17, 2020 9:27 AM EST

Today's Pre-Open Stock Movers

DURECT Corporation (Nasdaq: DRRX) 17.3% LOWER; announced that the U.S. Food and Drug Administration's (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) met yesterday to discuss the Class 2 New Drug Application (NDA) resubmission for POSIMIR® (bupivacaine extended-release solution). In a split vote on the key question, six advisory committee members voted to recommend that the efficacy, safety, and overall risk-benefit profile of POSIMIR support approval, while six did not support approval based on the information presented.

Tailored Brands, Inc. (NYSE:... More

IBM (IBM) Shares Edge Lower Following Downgrade

January 17, 2020 6:20 AM EST

IBM (NYSE: IBM) traded lower prior to the open following a downgrade from Overweight to Equalweight at Morgan Stanley with a price target of $155.. Shares were down 1.3%.

... More

UPDATE: Morgan Stanley Downgrades IBM (IBM) to Equalweight

January 17, 2020 4:03 AM EST

(Updated - January 17, 2020 9:03 AM EST)

(updated to add analyst comments)

Morgan Stanley analyst Katy Huberty downgraded IBM (NYSE: IBM) from Overweight to Equalweight with a price target of $155.00 (from $170.00).

The analyst commented, "Our AlphaWise CIO survey provides new... More